Helmlin, Hans-Jörg; Bracher, Katrin; Bourquin, Daniel; Vonlanthen, David; Brenneisen, Rudolf Max; Styk, Juraj (1996). Analysis of 3,4-Methylenedioxymethamphetamine (MDMA) and its Metabolites in Plasma and Urine by HPLC-DAD and GC-MS. Journal of analytical toxicology, 20(6), pp. 432-440. Oxford University Press 10.1093/jat/20.6.432
|
Text
20-6-432.pdf - Published Version Available under License Publisher holds Copyright. Download (1MB) | Preview |
In Europe, the compound 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy, Adam), in addition to cannabis, is the most abused illicit drug at all-night “techno” parties. Methods for the determination of MDMA and its metabolites, 4-hydroxy-3-methoxymethamphetamine (HMMA), 3,4-dihydroxymethamphetamine (HHMA), 3,4-methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxyamphetamine (HMA), and 3,4-dihydroxyamphetamine (HHA), in biological fluids were established. Plasma and urine samples were collected from two patients in a controlled clinical study over periods of 9 and 22 h, respectively. MDMA and MDA were determined in plasma and urine by reversed-phase high-performance liquid chromatography with diode array detection (HPLC-DAD) after solid-phase extraction on cation-exchange columns. Acidic or enzymatic hydrolysis was necessary to detect HMMA, HMA, HHMA, and HHA, which are mainly excreted as glucuronides. Gas chromatography-mass spectrometry (GC-MS) was used for confirmation. Sample extraction and on-disc derivatization with heptafluorobutyric anhydride (HFBA) were performed on Toxi-Lab SPEC solid-phase extraction concentrators. After administration of a single oral dose of 1.5 mg/kg body weight MDMA, peak plasma levels of 331 ng/mL MDMA and 15 ng/mL MDA were measured after 2 h and 6.3 h, respectively. Peak concentrations of 28.1 µg/mL MDMA in urine appeared after 21.5 h. Up to 2.3 µg/mL MDA, 35.1 µg/mL HMMA, and 2.1 µg/mL HMA were measured within 16–21.5 h. Conjugated HMMA and HHMA are the main urinary metabolites of MDMA.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Phytopharmakologie, Bioanalytik & Pharmakokinetik [discontinued] 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Phytopharmakologie, Bioanalytik & Pharmakokinetik [discontinued] |
UniBE Contributor: |
Brenneisen, Rudolf Max |
ISSN: |
0146-4760 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Marceline Brodmann |
Date Deposited: |
02 Sep 2020 16:12 |
Last Modified: |
05 Dec 2022 15:13 |
Publisher DOI: |
10.1093/jat/20.6.432 |
BORIS DOI: |
10.7892/boris.116034 |
URI: |
https://boris.unibe.ch/id/eprint/116034 |